Dr. Reddy's Laboratories (RDY) reported fiscal Q3 earnings Thursday of $0.20 per diluted share, up from $0.19 a year earlier.
Three analysts polled by FactSet expected $0.21.
Revenue for the quarter ended Dec. 31 was $977 million, compared with $843 million a year earlier.
Analysts surveyed by FactSet expected $950.5 million.
RDY shares were down 5.2% in recent trading.
Price: 14.31, Change: -0.79, Percent Change: -5.20
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。